Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 630-640
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.630
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.630
Figure 1 Causes of elevated carbohydrate antigen 19-9.
CA 19-9: carbohydrate antigen 19-9.
Figure 2 Interrelation between Lewis phenotype, carbohydrate antigen 19-9 and pancreatic ductal adenocarcinoma.
CA 19-9: carbohydrate antigen 19-9; PDAC: Pancreatic ductal adenocarcinoma.
Figure 3 Usefulness of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma management.
CA 19-9: carbohydrate antigen 19-9; PDAC: Pancreatic ductal adenocarcinoma.
- Citation: Balaban DV, Marin FS, Manucu G, Zoican A, Ciochina M, Mina V, Patoni C, Vladut C, Bucurica S, Costache RS, Ionita-Radu F, Jinga M. Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer. World J Clin Oncol 2022; 13(7): 630-640
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/630.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.630